Guideline reviews device-based therapies as potential adjunctive strategies for cardiorenal syndrome

This guideline review examines the role of device-based therapies for patients with cardiorenal syndrome (CRS). It does not report specific study designs, sample sizes, comparators, or primary outcomes from primary research. Instead, it offers a current perspective on how these interventions might fit into clinical management.

The main finding is that device-based therapies have shown potential as adjunctive strategies to address pathophysiologic mechanisms not adequately addressed by pharmacologic approaches alone. No specific effect sizes, absolute numbers, or statistical measures are reported. The review suggests implementing a phenotype-driven stepwise management algorithm.

Safety and tolerability data for these device-based approaches are not reported in this guideline document. The review emphasizes that practical application requires individualized patient selection determined by underlying hemodynamic phenotype, renal sodium avidity, diuretic responsiveness, and congestion burden. Key practical considerations include procedural risk and integration into existing care pathways.

As a review article offering perspective and suggestions rather than reporting primary study results, the evidence strength is limited. The guideline presents device therapies as potential adjunctive strategies, indicating an association rather than proven efficacy. Clinicians should interpret these suggestions cautiously while awaiting more definitive evidence from clinical trials.